Genetics of QT Prolongation With Antiarrhythmics

Trial Information
Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Observational
Summary

To assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being loaded with dofetilide or sotalol.

Am I eligible for this trial?
Participation Requirements
Sex:
All
Minimum Age:
18
Healthy Volunteers:
No

• All patients admitted for dovetailed or sotalol initiation for clinical purposes.

Where is this trial taking place?
United States
Colorado
University of Colorado Hospital
Recruiting
Aurora
Massachusetts
Beth Israel Deaconess Medical Center
Completed
Boston
Massachusetts General Hospital
Recruiting
Boston
Minnesota
Mayo Clinic
Recruiting
Rochester
Ohio
Cleveland Clinic
Recruiting
Cleveland
Who do I contact about this trial?
Primary
Christopher Newton-Cheh, MD, MPH
cnewtoncheh@mgh.harvard.edu
617-724-6158
Backup
Elizabeth Farland, BS
efarland@mgh.harvard.edu
617-643-6328
When is this trial taking place?
Start Date: January 2014
Estimated Completion Date: July 1, 2022
How many participants will be in this trial?
Target number of participants: 1000
What treatment is being studied in this trial?
Dofetilide patients
Patients admitted for dofetilide initiation
Sotalol patients
Patients admitted for sotalol initiation
Who are the authors of this trial?
Christopher Newton-Cheh
What other conditions are being studied in this trial?

This content was sourced from clinicaltrials.gov